Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study will include subjects with an abnormal glucose tolerance test. Using a crossover
design, we will evaluate the insulin sensitivity and intracellular lipid content of the
heart, liver and skeletal muscle of subjects before and after therapy with Rosiglitazone and
placebo. We hypothesize that Rosiglitazone will improve insulin sensitivity in association
with reduced muscle lipid content that may arise either from increased lipid oxidation or
enhanced storage of fat in adipose tissue.